Loading
Bausch & Lomb Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Mar 2026.
Bausch & Lomb Corp: what insiders have been doing
Headquartered in Vaughan, United States, Bausch & Lomb Corp belongs to the Health Care sector and traces its origins to 1853. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, 69 filings were filed, from 22 insiders.
Purchases and sales both appear in the filings: 9 purchases (9 insiders, €1.0M) and 3 sales (2 insiders, €1.0M). Taken together, the purchases exceed the sales by €12k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 7 senior executives, 1 finance chief and 1 chief executive. One trade stands out by size: a sale of €768k from Munsch Frederick, disclosed on 12 August 2026, or 0.015% of market capitalisation.
The data flag 8 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The most recent open-market purchase was published on 10 March 2026, 222 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 69 filings, this issuer sits above that mark. Our records for Bausch & Lomb Corp go back to 2022, with 12 purchases and 5 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 5.10 bn USD and net income of -360.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
210
Thresholds
n/a
Buy Volume
€2M
12 ops. · all time
Sell Volume
€641M
5 ops. · all time
Who traded when
BuySaleAndrew C. von Eschenbach2 buys2 sales
Brent L. Saunders2 buys
A. Robert D. Bailey1 buy
Eduardo Alfonso1 buy
Frederick Munsch1 sale
Ling Karen1 buy
+4 other insiders
Since the insiders bought
- -6.6%Entry US$17.50 · Close 15 Oct 2026 US$16.35
- -6.6%Entry US$17.50 · Close 15 Oct 2026 US$16.35
- -6.6%Entry US$17.50 · Close 15 Oct 2026 US$16.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Bausch & Lomb Corp Buy (bullish), based on 14 analysts. Average price target: US$19.39.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,204 of 24,148 companies
27.9
score / 100
Value25
Quality31
FCF yld-1.1%
Earn yld-6.1%
EV/EBITDA21.0x
ROE-2.5%
Gross mgn60%
Net mgn-7.1%
Debt/EBITDA9.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.66
Analyst consensus
14 analystsBuy
US$16.00Target US$19.39(+16%)US$24.00
Income statement
RevenueUS$5.1B
Gross profitUS$3.1B60% margin
EBITDAUS$525M10% margin
Net income-US$360M-3.2% margin
Valuation
PER (forward)15.0x
P/Book0.9x
Beta0.56
Balance sheet & cash
Market capUS$6B
Total debtUS$5.1B
Free Cash Flow-US$66M
Debt / Equity79%
Profitability & ownership
ROE-2.5%
ROA1.8%
% insiders87.3%
% institutions11.1%
Last declaration on 28 September 2026
Declarations210 total
4,500 shares@ US$16.830.0012% mcap19.5% of flowCommonSEC144:0001959173-26-007126
11,776 shares0Common Shares, No Par ValueSEC:0001860742-26-000102:0
11,776 shares0Common Shares, No Par ValueSEC:0001860742-26-000100:0
11,776 shares0Common Shares, No Par ValueSEC:0001860742-26-000105:0
52,900 shares@ US$16.780.015% mcap46.4% of flowCommon Shares, No Par ValueSEC:0001860742-26-000096:0
52,900 shares@ US$16.78420.015% mcap46.4% of flowCommonSEC144:0001959173-26-005847
12,500 shares@ US$16.500.0034% mcap21.5% of flowCommon Shares, No Par ValueSEC:0001193125-26-343029:0
6,059 shares@ US$16.580.0016% mcap10.5% of flowCommon Shares, No Par ValueSEC:0001193125-26-343029:1
6,059 shares@ US$16.57530.0016% mcap10.5% of flowcommonSEC144:0001957799-26-000148
33,557 shares0Common Shares, No Par ValueSEC:0001860742-26-000090:0
281,879 shares0Common Shares, No Par ValueSEC:0001860742-26-000089:1
16,778 shares0Common Shares, No Par ValueSEC:0001860742-26-000091:0
50,335 shares0Common Shares, No Par ValueSEC:0001860742-26-000092:0
20,973 shares0Common Shares, No Par ValueSEC:0001860742-26-000093:0
9,091 shares0Common Shares, No Par ValueSEC:0001860742-26-000094:0
16,778 shares0Common Shares, No Par ValueSEC:0001860742-26-000095:0
4,231 shares@ US$16.760.0012% mcap1.7% of flowCommon Shares, No Par ValueSEC:0001860742-26-000089:0
12,500 shares@ US$16.49540.0034% mcap21.5% of flowCommonSEC144:0001959173-26-005713
1,008 sharesCommon Shares, No Par ValueSEC:0001860742-26-000084:0
15,842 shares@ US$15.780.0037% mcap58.3% of flowCommon Shares, No Par ValueSEC:0001860742-26-000075:0
15,842 shares@ US$15.780.0037% mcap71.9% of flowCommon Shares, No Par ValueSEC:0001860742-26-000072:0
15,842 shares@ US$15.780.0037% mcap46.7% of flowCommon Shares, No Par ValueSEC:0001860742-26-000076:0
15,842 shares@ US$15.780.0037% mcap67.5% of flowCommon Shares, No Par ValueSEC:0001860742-26-000077:0
15,842 shares@ US$15.780.0037% mcap78.1% of flowCommon Shares, No Par ValueSEC:0001860742-26-000078:0
15,842 shares@ US$15.780.0037% mcap49.8% of flowCommon Shares, No Par ValueSEC:0001860742-26-000079:0
25 of 210 declarations
About Bausch & Lomb Corp
Bausch & Lomb Corp is a company focused on eye care, providing products such as contact lenses and care solutions. It is listed on NASDAQ under the ticker BLCO.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
